Navigation Links
Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
Date:12/27/2007

endpoints include duration of response, progression-free survival and overall survival.

Owen A. O'Connor, MD, PhD, Director, Lymphoid Development & Malignancy Program and Chief, Lymphoma Service, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, is the international study chair.

In accordance with the PROPEL study design, in January 2007, the DMC completed an interim analysis of safety data based on the first 10 patients enrolled to the study who completed at least one cycle of treatment with PDX, and recommended that the trial continue per the protocol. Also in accordance with the study design, in September 2007, an interim analysis of patient response and safety data was conducted based on the first 35 patients enrolled to the study who completed at least one cycle of treatment with PDX. The results of the interim analysis of patient response data exceeded the pre-specified threshold for continuation of the trial, which required a minimum of four responses (complete or partial) out of the first 35 evaluable patients, as determined by independent oncology review. In addition, the DMC identified no major safety concerns and recommended that the trial continue per the protocol.

The PROPEL trial is being conducted under an agreement with the United States Food and Drug Administration (FDA) under its special protocol assessment (SPA) process. The SPA process allows for FDA evaluation of a clinical trial protocol intended to form the primary basis of an efficacy claim in support of an NDA, and provides an agreement that the study design, including trial size, clinical endpoints and/or data analyses are acceptable to the FDA. The FDA granted orphan drug designation to PDX for the treatment of T-cell lymphoma in July 2006 and granted fast track designation to PDX for the treatment of patients with T-cell lymphoma in September 2006. In April 2007, the Commission of the European Communities, with a favorable opinion of the Comm
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ... the District of New Jersey ... against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... that U.S. Patent No. 6,765,117 is both valid and ... its generic product until the expiration of that patent ...
(Date:8/29/2014)... 2014 Diseases largely eradicated in ... returning. Measles was declared eliminated in 2000, yet the ... August 15—the highest incidence in 20 years. In July, ... whooping cough a problem of "epidemic proportions." ... dying from these preventable diseases—in part because some parents ...
(Date:8/29/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... that results in demyelination, axonal transection, and neurodegeneration. The ... by the immune system, which targets neurons within the ... disease in which the damage of the myelin sheath ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... Sept. 21, 2011 SmallCapVoice.com, Inc. announced ... Alarm Concepts Holding, Inc. (OTCQB: MDHI), manufacturer ... alarm system that allows the users to ... is now available. The interview can be ...
... organiser UBM Conferences , a division of UBM ... introduced CPhI Lunchtime Education Series to be hosted 25th ... Worldwide event which is focused on pharmaceutical ingredients. Organised ... workshop format with six interactive sessions over the three ...
Cached Medicine Technology:A New Audio Interview with Medical Alarm Concepts Holdings, Inc., CEO, Howard Teicher, is now at SmallCapVoice.com 2CPhI Conferences Introduces New Lunchtime Education Series 2
(Date:8/29/2014)... According to the latest review published by DailyGossip.org, this ... safely and naturally. The new method promises great efficiency in ... , Daily Gossip writes in its Flat Belly Forever ... how to eliminate the extra pounds, it will also show ... to body modeling. , The method reveals some breakthrough ...
(Date:8/29/2014)... The new review that can be read ... holistic system that will permanently eliminate the symptoms of this ... can achieve a cure in as fast as 30 to ... only about one week. , The Tinnitus Miracle review ... as mild hearing loss, pain in the ear and dizziness. ...
(Date:8/29/2014)... CO (PRWEB) August 29, 2014 Panic ... attack is the feeling of intense stress and fear, ... life of the sufferer, causing insecurity and affecting relationships. ... factors and there are many symptoms that patients can ... are among these symptoms. Overcoming panic attacks is extremely ...
(Date:8/29/2014)... Dr. Parsa Mohebi, founder of US ... practice to Parsa Mohebi Hair Restoration. Since officially launching ... of hair loss patients throughout Southern California. It even ... Los Angeles, Beverly Hills, and Orange County. These patients ... many of which Dr. Mohebi perfected through new technology ...
(Date:8/29/2014)... 29, 2014 According to a CNN ... Overdoses (8/25), a new study found that those ... have seen a significant decrease in the number of ... a ten year period, and comparing various states with ... find that there was about a 25% decrease in ...
Breaking Medicine News(10 mins):Health News:Flat Belly Forever Review Exposes the Way to Eliminate Body Fat Easily 2Health News:Tinnitus Miracle Review Reveals How to Gain Tinnitus Relief in 7 Days 2Health News:60 Second Panic Solution Review Exposes Simple Panic Attacks Remedy 2Health News:US Hair Restoration Changes Name to Parsa Mohebi Hair Restoration to Better Reflect Founder 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 3
... as Titan of Business & ... ... Washington DC,business community leaders achieved extraordinary fundraising success on,Saturday ... guests,to the Washington Convention Center for one of DC,s largest ...
... Park Ridge, Ill. (April 3, 2008) Choline, an essential nutrient ... 24 percent reduced risk of breast cancer, according to a ... of Health (NIH), to be published in The FASEB Journals ... body of evidence that links egg consumption to a decreased ...
... like dementia are on the rise. And, thanks to ... will be at the forefront of research dealing with ... research teams have won National Health and Medical Research ... in hospitals, transitions to residential care and ascertaining the ...
... 3, 2008 TeamStaff, Inc.,(Nasdaq: TSTF ) ... today announced that it entered into a three ... agreement with Sovereign,Business Capital ("SBC", formerly Business Alliance ... loan credit facility, SBC takes,assignment of TeamStaff,s prior ...
... Edwards,Lifesciences Corporation (NYSE: EW ), a global ... disease, today announced that,its chairman and chief executive ... trading plan under Rule 10b5-1 of the Securities ... similar plan that expired last,month., The new ...
... degree made attempt, but economic status also plays role ... that promote quitting smoking are more likely to have ... dangers of secondhand smoke have a similar effect on ... Wisconsin study. , In 2002 and 2003, researchers ...
Cached Medicine News:Health News:DC's Business Leaders Raise $3.3 Million at Annual Leukemia Ball Featuring Jay Leno 2Health News:DC's Business Leaders Raise $3.3 Million at Annual Leukemia Ball Featuring Jay Leno 3Health News:DC's Business Leaders Raise $3.3 Million at Annual Leukemia Ball Featuring Jay Leno 4Health News:Essential nutrient found in eggs reduces risk of breast cancer by 24 percent 2Health News:Essential nutrient found in eggs reduces risk of breast cancer by 24 percent 3Health News:Better care for dementia patients through new funding 2Health News:TeamStaff Announces Amended Revolving Credit Facility with Sovereign Business Capital 2Health News:TeamStaff Announces Amended Revolving Credit Facility with Sovereign Business Capital 3Health News:Edwards Lifesciences' Chairman and CEO Adopts New 10b5-1 Stock Trading Plan to Replace Recently Expired Plan 2Health News:Better-Educated Smokers More Likely to Quit After Seeing Ads 2
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
... The Illuminated Phoroptor features lighted dials ... to perform refractions in the darkened setting ... pen light and leave the lights off ... features lighted sphere, cylinder power and cylinder ...
... The Reichert CT200 Tonometer ... the XCEL 250 and XCEL ... also compatible with other Zeiss-style ... mounted on the top of ...
Medicine Products: